{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:38:07Z","timestamp":1792697887977,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.therap.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:52:57Z","timestamp":1741143177000},"page":"639-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical consequences of varenicline shortage: A study on the French national pharmacovigilance database"],"prefix":"10.1016","volume":"80","author":[{"given":"Am\u00e9lie","family":"Lepert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Bourneau-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gentil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Brunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Briet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.02.009_bib0195","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2022.0395","article-title":"Treatment of tobacco smoking: a review","volume":"327","author":"Rigotti","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2025.02.009_bib0200","series-title":"WHO: a guide for tobacco users to quit","year":"2014"},{"key":"10.1016\/j.therap.2025.02.009_bib0205","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/03007995.2020.1729708","article-title":"Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations","volume":"36","author":"Tonstad","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.therap.2025.02.009_bib0210","series-title":"List of classifications\u00a0\u2013\u00a0IARC monographs on the identification of carcinogenic hazards to humans","year":"2024"},{"key":"10.1016\/j.therap.2025.02.009_bib0215","unstructured":"European Medicines Agency. Meeting highlights from the Committee for Medicinal Products Human Use (CHMP) 13\u201316 September 2021. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021 [Accessed 20 February 2025]."},{"key":"10.1016\/j.therap.2025.02.009_bib0220","series-title":"Champix (varenicline)\u00a0\u2013\u00a0lots to be recalled due presence of impurity N-nitroso-varenicline above the Pfizer acceptable daily intake limit","year":"2021"},{"key":"10.1016\/j.therap.2025.02.009_bib0225","series-title":"Information de s\u00e9curit\u00e9 \u2013\u00a0Champix (var\u00e9nicline)\u00a0\u2013 rappel de lot","year":"2021"},{"key":"10.1016\/j.therap.2025.02.009_bib0230","series-title":"Tobacco","year":"2023"},{"key":"10.1016\/j.therap.2025.02.009_bib0235","series-title":"Statistic\u00a0\u2013\u00a0tobacco consumption statistics explained","year":"2022"},{"key":"10.1016\/j.therap.2025.02.009_bib0240","series-title":"Journ\u00e9e mondiale sans tabac. Quelle pr\u00e9valence du tabagisme en France\u00a0? Qui sont les fumeurs\u00a0?","year":"2020"},{"key":"10.1016\/j.therap.2025.02.009_bib0245","series-title":"Inclusion of varenicline tartrate in the WHO model list of essential medicines (EML)","year":"2021"},{"key":"10.1016\/j.therap.2025.02.009_bib0250","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2025.02.009_bib0255","series-title":"Chantix(R) (varinicline) tablets","year":"2009"},{"key":"10.1016\/j.therap.2025.02.009_bib0260","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/ADM.0000000000001171","article-title":"Effectiveness and safety of varenicline for smoking cessation: an overview and meta-analysis","volume":"17","author":"Shang","year":"2023","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2025.02.009_bib0265","series-title":"Point d\u2019information sur le Champix (varenicline)","year":"2007"},{"key":"10.1016\/j.therap.2025.02.009_bib0270","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3109\/10826084.2015.1133646","article-title":"Safety of varenicline for smoking cessation in psychiatric and addicts patients","volume":"51","author":"Raich","year":"2016","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.therap.2025.02.009_bib0275","doi-asserted-by":"crossref","first-page":"e0143490","DOI":"10.1371\/journal.pone.0143490","article-title":"Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: a double-blind randomized trial","volume":"11","author":"Smith","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2025.02.009_bib0280","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3389\/fpsyt.2018.00428","article-title":"Efficacy and safety of varenicline for smoking cessation in schizophrenia: a meta-analysis","volume":"9","author":"Ahmed","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2025.02.009_bib0285","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.4088\/JCP.11r07410","article-title":"Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies","volume":"73","author":"Cerimele","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.therap.2025.02.009_bib0290","series-title":"Health effects of cigarette smoking","year":"2024"},{"key":"10.1016\/j.therap.2025.02.009_bib0295","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.berh.2008.09.011","article-title":"Smoking and inflammatory diseases","volume":"22","author":"Vittecoq","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.therap.2025.02.009_bib0300","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S2213-2600(23)00184-4","article-title":"Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic","volume":"11","author":"Lang","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.therap.2025.02.009_bib0305","series-title":"IARC. Some N-nitroso compounds","year":"1978"},{"key":"10.1016\/j.therap.2025.02.009_bib0310","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1183\/13993003.00359-2016","article-title":"Risk factors for lung cancer worldwide","volume":"48","author":"Malhotra","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.therap.2025.02.009_bib0315","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S1470-2045(04)01633-X","article-title":"Smokeless tobacco and tobacco-related nitrosamines","volume":"5","author":"Cogliano","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.therap.2025.02.009_bib0320","series-title":"Nitrosamine impurities","year":"2020"},{"key":"10.1016\/j.therap.2025.02.009_bib0325","series-title":"Recommended acceptable intake limits for nitrosamine drug substance-related impurities (NDSRIs)","year":"2025"},{"key":"10.1016\/j.therap.2025.02.009_bib0330","series-title":"Laboratory analysis of varenicline products","author":"Research C for DE","year":"2021"},{"key":"10.1016\/j.therap.2025.02.009_bib0335","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/carcin\/9.6.875","article-title":"Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke","volume":"9","author":"Hecht","year":"1988","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.therap.2025.02.009_bib0340","series-title":"Updates and press announcements on nitrosamine in varenicline","year":"2022"},{"key":"10.1016\/j.therap.2025.02.009_bib0345","series-title":"Commission de transparence, avis du 9 novembre 2016, var\u00e9nicline","year":"2016"},{"key":"10.1016\/j.therap.2025.02.009_bib0350","series-title":"Commission de transparence, avis 21 avril 2021, var\u00e9nicline","year":"2021"},{"key":"10.1016\/j.therap.2025.02.009_bib0355","unstructured":"National Center for Smoking Cessation and Training (NCSCT). Bupropion. https:\/\/www.ncsct.co.uk. [Accessed 20 February 2025]."},{"issue":"5","key":"10.1016\/j.therap.2025.02.009_bib0360","first-page":"CD006103","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"5","author":"Livingstone-Banks","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2025.02.009_bib0365","series-title":"Two new tobacco cessation medicines added to the WHO essential medicines list","year":"2021"},{"key":"10.1016\/j.therap.2025.02.009_bib0370","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1164\/rccm.202005-1982ST","article-title":"Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society Clinical Practice Guideline","volume":"202","author":"Leone","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.therap.2025.02.009_bib0375","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bcp.15550","article-title":"Adverse drug reaction related to drug shortage: a retrospective study on the French National Pharmacovigilance Database","volume":"89","author":"Bourneau-Martin","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.02.009_bib0380","article-title":"Adverse drug effect in the context of drug shortage: the CIRUPT prospective study from the French pharmacovigilance network","author":"Bourneau-Martin","year":"2024","journal-title":"Eur J Hosp Pharm Sci Pract"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572500037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572500037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:21:07Z","timestamp":1776446467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059572500037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S004059572500037X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.02.009","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical consequences of varenicline shortage: A study on the French national pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}